S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
NYSE:NVS

Novartis (NVS) Stock Price, News & Analysis

$100.97
+1.00 (+1.00%)
(As of 12/29/2023 ET)
Today's Range
$100.34
$101.04
50-Day Range
$92.29
$100.97
52-Week Range
$79.98
$105.61
Volume
960,276 shs
Average Volume
1.51 million shs
Market Capitalization
$214.02 billion
P/E Ratio
27.14
Dividend Yield
2.25%
Price Target
$85.00

Novartis MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
15.8% Downside
$85.00 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.87mentions of Novartis in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
9.59%
From $6.57 to $7.20 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

772nd out of 950 stocks

Pharmaceutical Preparations Industry

371st out of 442 stocks


NVS stock logo

About Novartis Stock (NYSE:NVS)

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

NVS Stock Price History

NVS Stock News Headlines

New Year's Sale: Get MarketBeat All Access Free For 30 Days
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Click the link to claim your $300.00 account credit and free 30-day subscription
Novartis (NVS) Stock Moves -1.17%: What You Should Know
NVS Jan 2024 40.000 put
Novartis (NVS) Stock Sinks As Market Gains: Here's Why
Claim Your $300 MarketBeat Account Credit
Click the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)
Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug
Novartis: Post Investor Day, Higher Guidance Priced In
3 Large Drug Stocks That Have Outperformed Industry YTD
See More Headlines
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/23/2023
Today
12/31/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/07/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
101,703
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$85.00
High Stock Price Target
$85.00
Low Stock Price Target
$85.00
Potential Upside/Downside
-15.8%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$6.96 billion
Pretax Margin
17.89%

Debt

Sales & Book Value

Annual Sales
$50.55 billion
Cash Flow
$6.30 per share
Book Value
$28.03 per share

Miscellaneous

Outstanding Shares
2,119,600,000
Free Float
2,119,388,000
Market Cap
$214.02 billion
Optionable
Optionable
Beta
0.55

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Vasant Narasimhan (Age 47)
    Chief Executive Officer
    Comp: $5.91M
  • Mr. Harry Kirsch (Age 58)
    Chief Financial Officer
    Comp: $2.99M
  • Dr. Steffen Lang Ph.D. (Age 56)
    President of Operations
    Comp: $2.45M
  • Dr. Klaus Moosmayer Ph.D. (Age 55)
    Chief Ethics, Risk & Compliance Officer
    Comp: $1.63M
  • Ms. Karen L. Hale (Age 55)
    Chief Legal Officer
    Comp: $2.46M
  • Dr. Robert Kowalski Pharm.D. (Age 55)
    Chief People & Organization Officer
    Comp: $2.21M
  • Mr. Victor Bulto
    President of US
  • Dr. Shreeram Aradhye M.D. (Age 60)
    President of Global Drug Development & Chief Medical Officer
    Comp: $2.4M
  • Mr. Aharon Gal Ph.D.
    Chief Strategy & Growth Officer
  • Dr. Fiona H. Marshall Ph.D. (Age 59)
    President of BioMedical Research
    Comp: $5.3M














NVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Novartis stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View NVS analyst ratings
or view top-rated stocks.

What is Novartis' stock price target for 2024?

5 brokers have issued 12-month target prices for Novartis' shares. Their NVS share price targets range from $85.00 to $85.00. On average, they expect the company's stock price to reach $85.00 in the next twelve months. This suggests that the stock has a possible downside of 15.8%.
View analysts price targets for NVS
or view top-rated stocks among Wall Street analysts.

How have NVS shares performed in 2023?

Novartis' stock was trading at $90.72 on January 1st, 2023. Since then, NVS shares have increased by 11.3% and is now trading at $100.97.
View the best growth stocks for 2023 here
.

When is Novartis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 7th 2024.
View our NVS earnings forecast
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) issued its quarterly earnings data on Monday, October, 23rd. The company reported $1.74 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.04. The business had revenue of $11.78 billion for the quarter, compared to analyst estimates of $12.05 billion. Novartis had a net margin of 15.35% and a trailing twelve-month return on equity of 28.27%. During the same quarter in the prior year, the business earned $1.58 earnings per share.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Thursday, February 2nd. Investors of record on Friday, March 10th will be given a dividend of $3.4694 per share on Monday, March 20th. This represents a yield of 2.6%. The ex-dividend date is Thursday, March 9th. This is an increase from the stock's previous annual dividend of $1.18.
Read our dividend analysis for NVS
.

Is Novartis a good dividend stock?

Novartis (NYSE:NVS) pays an annual dividend of $2.27 per share and currently has a dividend yield of 2.25%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 61.02%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVS will have a dividend payout ratio of 31.53% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVS.

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Novartis have any subsidiaries?
The following companies are subsidiares of Novartis: 1 A Pharma GmbH, Abadia Retuerta S.A, Admune Therapeutics, Advanced Accelerator Applications, Advanced Accelerator Applications, Advanced Accelerator Applications International SA, Advanced Accelerator Applications S.A., Advanced Accelerator Applications S.r.l., Advanced Accelerator Applications USA Inc., Aeropharm GmbH, Alcon, Alcon – Couvreur NV, Amblyotech, Amblyotech Inc., Arctos Medical, Arctos Medical AG, Australia Pty Ltd, Beijing Novartis Pharma Co. Ltd., BioMedical Research Co. Ltd., CELLforCURE, Cadent Therapeutics, Cadent Therapeutics Cambridge, Cellerys, Cellerys AG, CellforCure, Chiron Corporation, Ciba-Geigy Japan Limited, Co. Ltd, CoStim Pharmaceuticals, CoStim Pharmaceuticals Inc., Coalesce Product Development Limited, Corthera, Development Co. Ltd., EBEWE Pharma Ges.m.b.H Nfg. KG, Encore Vision, Endocyte, Endocyte Inc., Eon Labs Inc., Farmanova Saglik Hizmetleri Ltd, Fougera Pharmaceuticals, Fougera Pharmaceuticals Inc, Gyroscope Therapeutics, HEXAL AG, Hexal, IDB Holland BV, Iberica S.L.U., Ilaçlari Sanayi ve Ticaret A.S, JSC Sandoz, Japat AG, Kedalion Therapeutics Inc., Lek Pharmaceuticals d.d., Lek S.A., Manufacturing Pte Ltd , Navigate BioPharma Services Inc, Neutec Pharma Limited, Novartis (Hellas) S.A.C.I., Novartis (Singapore) Pte Ltd, Novartis (Taiwan) Co. Ltd, Novartis (Thailand) Limited, Novartis Argentina S.A., Novartis Australia Pty Ltd, Novartis Austria GmbH, Novartis Biociências S.A., Novartis Biosciences Perú S.A., Novartis Bioventures AG, Novartis Business Services GmbH, Novartis Capital Corporation, Novartis Chile S.A., Novartis Corporation, Novartis Corporation Sdn. Bhd., Novartis Deutschland GmbH, Novartis Ecuador S.A., Novartis Farma S.p.A., Novartis Farma – Produtos Farmacêuticos S.A., Novartis Farmacéutica S.A, Novartis Farmacéutica S.A. de C.V., Novartis Finance Corporation, Novartis Finance S.A., Novartis Finance Services Ltd, Novartis Finland Oy Espoo, Novartis Gene Therapies, Novartis Gene Therapies EU Limited, Novartis Gene Therapies Inc., Novartis Grimsby Limited, Novartis Groupe France S.A., Novartis Healthcare A/S, Novartis Healthcare Philippines Inc., Novartis Healthcare Private Limited, Novartis Holding AG, Novartis Hungary Healthcare Limited Liability Company, Novartis India Limited, Novartis Inflammasome Research, Novartis Integrated Services Limited, Novartis International AG, Novartis International Pharmaceutical Investment AG, Novartis Investment Ltd, Novartis Investments S.à r.l., Novartis Ireland Limited, Novartis Israel Ltd, Novartis Korea Ltd., Novartis Middle East FZE, Novartis Netherlands B.V., Novartis Neva LLC, Novartis New Zealand Ltd, Novartis Norge AS, Novartis Ophthalmics AG, Novartis Optogenetics Research Inc., Novartis Overseas Investments AG, Novartis Pharma (Logistics) Inc., Novartis Pharma (Pakistan) Limited, Novartis Pharma AG, Novartis Pharma B.V. , Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma K.K., Novartis Pharma LLC, Novartis Pharma Maroc SA, Novartis Pharma NV, Novartis Pharma Produktions GmbH, Novartis Pharma S.A.E., Novartis Pharma S.A.S., Novartis Pharma Schweiz AG, Novartis Pharma Schweizerhalle AG, Novartis Pharma Services AG, Novartis Pharma Services Romania S.R.L., Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Limited, Novartis Pharmaceuticals UK Limited, Novartis Poland Sp. z o.o., Novartis Portugal S.G.P.S. Lda., Novartis Ringaskiddy Limited, Novartis Saglik Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S, Novartis Saudi Ltd., Novartis Securities Investment Ltd, Novartis Services Inc., Novartis Slovakia s.r.o., Novartis South Africa (Pty) Ltd, Novartis Sverige AB, Novartis UK Limited, Novartis US Foundation, Novartis Vaccines and Diagnostics Inc, Novartis Vietnam Company Limited, Novartis de Colombia S.A., Novartis de Venezuela S.A., Novartis s.r.o., Oriel Therapeutics Inc., PT. Novartis Indonesia, Protez Pharmaceuticals, Pte Ltd, Research Inc, Salutas Pharma GmbH, Sandoz A/S, Sandoz AG, Sandoz B.V., Sandoz Canada Inc., Sandoz Egypt Pharma S.A.E., Sandoz Farmacéutica S.A., Sandoz Farmacêutica Lda., Sandoz GmbH, Sandoz Hungary Limited Liability Company, Sandoz Ilaç Sanayi ve Ticaret A.S., Sandoz Inc, Sandoz Industrial Products S.A, Sandoz International GmbH, Sandoz K.K., Sandoz Limited, Sandoz Manufacturing Inc., Sandoz NV, Sandoz Pharma K.K, Sandoz Pharmaceuticals AG, Sandoz Pharmaceuticals d.d., Sandoz Philippines Corporation, Sandoz Polska Sp. z o.o. , Sandoz Private Limited, Sandoz Pty Ltd, Sandoz S.A. de C.V, Sandoz S.A.S., Sandoz S.R.L., Sandoz S.p.A., Sandoz South Africa (Pty) Ltd, Sandoz Ukraine LLC, Sandoz d.o.o. farmaceutska industrija, Sandoz do Brasil Indústria Farmacêutica Ltda, Sandoz s.r.o., Selexys Pharmaceuticals Corporation, Shanghai Novartis Trading Ltd., Société par actions SANDOZ, Spinifex Pharmaceuticals, The Medicines Company, The Medicines Company, Triangle International Reinsurance Limited, Trinity River Insurance Co Ltd, Vedere Bio, Vedere Bio ll, Xiidra, Ziarco, and Ziarco Group Limited.
Read More
This page (NYSE:NVS) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -